Fermer le menu


RHEONOVA develops an innovative medical device dedicated to Cystic Fibrosis and COPD (Chronic Obstructive Pulmonary Disease) market. Rheomuco measures the viscoelasticity properties of the pulmonary secretions. Rheomuco allows Biotech & Pharma companies to validate the effectiveness of their drug candidates obtaining pharmacodynamics data throughout in vitro studies and clinical trials. The healthcare professionals who follow patients affected by a cystic fibrosis, will use the test as a surrogate endpoint. Rheomuco makes the prognostic of the evolution of the disease possible. Results will be used to adapt and anticipate treatments. For the pulmonologists, Rheomuco is a simple test to better diagnose and monitor the COPD, an under-diagnosed disease that affects 210 million people worldwide. For both diseases, the main benefit for patients is a personalized follow-up of their health status, particularly with a prognostic of the exacerbation phases to avoid hospitalization and heavy emergency treatment. The output is a simple parameter which assesses quantitatively the state of a disease. RHEONOVA can offer a wide range of devices to characterize other biological fluids: knowing and understanding their properties can diagnose pathologies, prove quantitatively the efficiency of a treatment from a mechanical point of view, and play the role of a companion test.


Strategic application domain: Medical Technologies

Application market: Pneumology - Respiratory Diseases, Others

Type of activity: Diagnostics, Medical device

Created on july 24th, 2014 - 10 employees



1270 rue de la piscine - Bât. Galilée 38400 Saint Martin d'Hères



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.